Apolipoprotein B (ApoB) is the structural protein of all atherogenic lipoproteins — LDL, IDL, VLDL, and Lp(a). The apob test measures the total number of these particles, providing a more complete picture of atherogenic burden than LDL cholesterol alone. Many lipid specialists consider ApoB a better cardiovascular risk marker than LDL, though it’s not yet part of routine lipid screening in most settings. This guide covers what ApoB measures, why it matters, normal ranges, and clinical applications.
Why ApoB matters more than LDL alone
Standard lipid panels measure LDL cholesterol — the amount of cholesterol carried in LDL particles. But the number of LDL particles matters more than the cholesterol content. Patients can have similar LDL cholesterol but very different particle counts.
Each atherogenic lipoprotein particle carries one ApoB molecule. ApoB measures the total number of atherogenic particles, regardless of cholesterol content per particle. High particle number with low cholesterol per particle (small dense LDL pattern) carries higher cardiovascular risk than low particle number with high cholesterol per particle.
Patients with metabolic syndrome and insulin resistance often have a “discordant” lipid profile — LDL cholesterol may look acceptable while ApoB and particle number are elevated.
Reference ranges
- Optimal: under 80 mg/dL (high cardiovascular risk patients)
- Acceptable: under 90 mg/dL (general population)
- Borderline: 90-110 mg/dL
- High: above 110 mg/dL
Treatment targets are similar to LDL targets adjusted for particle number considerations.
When ApoB testing is most useful
Discordant LDL and triglycerides: Patients with high triglycerides and “normal” LDL often have elevated ApoB. The pattern is common in metabolic syndrome, type 2 diabetes, and insulin resistance.
Treatment monitoring: ApoB on statin therapy may reveal residual particle excess despite acceptable LDL.
Family history: Patients with cardiovascular disease at younger ages or strong family history may benefit from ApoB testing for fuller risk assessment.
“Normal” lipid panels with cardiovascular events: ApoB sometimes reveals atherogenic burden missed by standard testing.
ApoB vs non-HDL cholesterol
Non-HDL cholesterol (total cholesterol minus HDL) approximates the atherogenic burden and is calculable from standard lipid panels without additional testing. Non-HDL captures most of what ApoB measures and is widely available at no extra cost.
For most patients, non-HDL cholesterol provides similar information to ApoB. ApoB adds value in specific scenarios — discordance between LDL and non-HDL, refined risk assessment in high-risk patients, and treatment monitoring.
Treatment of elevated ApoB
Standard cholesterol therapies lower ApoB:
- Statins: 30-50% reduction
- Ezetimibe: additional 15-20% reduction
- PCSK9 inhibitors: 50-60% additional reduction
- Bempedoic acid: 15-20% reduction
Treatment goals depend on cardiovascular risk and individual factors. The American College of Cardiology guidelines provide detailed treatment recommendations.
Frequently Asked Questions
Do I need to fast for ApoB testing?
Less critical than for triglycerides. Most labs prefer fasting for the full lipid context.
Should I get ApoB instead of a lipid panel?
ApoB complements rather than replaces the standard lipid panel. Both provide useful information.
Is ApoB testing covered by insurance?
Coverage varies. Many insurance plans cover ApoB when ordered with appropriate clinical justification.
What does high ApoB mean?
Elevated atherogenic particle number, indicating increased cardiovascular risk. Treatment with cholesterol-lowering therapy is typically indicated.
Should everyone get ApoB tested?
Not yet routine. Most useful for patients with discordant standard lipid findings, strong family history, or treatment-resistant disease.
The bottom line on the ApoB test
ApoB measures the total number of atherogenic lipoprotein particles, providing more complete cardiovascular risk information than LDL cholesterol alone. It’s particularly useful when standard lipid panels show discordance or when refined risk assessment is needed. Treatment with cholesterol-lowering therapy reduces ApoB. Discuss with your healthcare provider whether ApoB testing is appropriate for your situation.